Article
Brochure
Executive Resource
Insight Hub
Video
Ext. Publication
Home /
Insights & Resources
Insights & Resources
Start exploring insights from across the industries we serve, featuring the latest industry trends, compliance alerts, tax and accounting news and much more.
- Alternative Investments
- Banking
- Blockchain & Digital Assets
- Construction
- Consumer Products
- Energy Transition
- Financial Services
- Food & Beverage
- General Business
- Government
- Health Care
- Higher Education
- Hospitality & Entertainment
- Industrial Products
- Insurance
- Life Sciences
- Not-for-Profit
- Oil & Gas
- Oilfield Services
- Real Estate
- Renewable Fuels
- Technology
- Transportation & Logistics
- Accounting Advisory
- Artificial Intelligence
- Asset Management Consulting
- Asset Tracing
- Cybersecurity
- Data Privacy
- Digital Transformation
- Energy Compliance
- ESG Strategy & Consulting
- Family Law
- Forensics & Litigation
- Government Consulting
- Health Care Valuation
- IT Advisory
- Risk Advisory
- Transaction Advisory
- Trust & Estate
- Valuation
As risk evolves, life science companies must adapt valuation methods. Learn to better align risk, value and strategy in your decision-making process.
J.P. Morgan's Q1 2025 biopharma and medtech reports reveal larger deals, global growth and financial strategies shaping the life sciences industry.
Several updates to HB 8 will affect Texas community colleges and their state funding. Here’s the breakdown and how they will affect campuses.
Within the changing landscape of educational technology, schools face new risk factors that affect students, faculty and administrators.
Strategic property basis allocation focusing on land and building depreciation enhances real estate value while maximizing tax benefits for investors.
PodcastWeaver's Jeremy Winkler and Selina McUmber discuss insights and trends from the 2024 NCREIF conference on real estate, valuations and global future-shaping factors.
Weaver’s overview of the SEC’s 2025 examination priorities describe practices by investment advisers and others that may come under SEC review.
The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.
The biopharma industry has experienced a resurgence the first part of 2024. J.P. Morgan’s Q2 report shares critical insights into the future of the industry.
Join Becky Reeder and David Burch as they discuss 30 years of navigating the investment landscape and tactical strategies for emerging managers.
Recently, The Texas Higher Education Coordinating Board (THECB) released updates and clarifications to rules adopted in June 2023 for FY 2024. The updates apply to FY 2025 and include changes in four areas: Credentials of Value, Fundable Credentials, High-Demand Fields, and Methodology and Process Changes.
Common scenarios VC managers face as they prepare their valuations for their financial statement audit and tips for approaching the valuation analysis.
